Dermapharm Holding SE
DMPHF
$38.50
-$2.12-5.23%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 312.65M | 321.24M | 314.37M | 345.82M | 305.47M |
| Total Other Revenue | -- | -- | 799.50K | -- | -- |
| Total Revenue | 312.65M | 321.24M | 315.17M | 345.82M | 305.47M |
| Cost of Revenue | 103.68M | 111.63M | 127.60M | 129.94M | 113.54M |
| Gross Profit | 208.98M | 209.61M | 187.57M | 215.89M | 191.93M |
| SG&A Expenses | 85.61M | 79.33M | 84.23M | 71.74M | 79.52M |
| Depreciation & Amortization | 23.10M | 21.03M | 19.01M | 22.82M | 25.64M |
| Other Operating Expenses | 55.86M | 51.86M | 3.86M | 54.53M | 56.14M |
| Total Operating Expenses | 268.25M | 263.85M | 234.70M | 279.03M | 274.84M |
| Operating Income | 44.40M | 57.39M | 80.47M | 66.80M | 30.63M |
| Income Before Tax | 36.91M | 52.27M | 36.83M | 51.45M | 28.84M |
| Income Tax Expenses | 13.20M | 17.33M | 16.53M | 15.43M | 10.71M |
| Earnings from Continuing Operations | 23.71M | 34.93M | 20.31M | 36.02M | 18.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.30K | 218.90K | 1.56M | -413.40K | 455.30K |
| Net Income | 23.71M | 35.15M | 21.86M | 35.61M | 18.59M |
| EBIT | 44.40M | 57.39M | 80.47M | 66.80M | 30.63M |
| EBITDA | 67.17M | 78.39M | 88.12M | 89.17M | 54.62M |
| EPS Basic | 0.44 | 0.65 | 0.41 | 0.66 | 0.34 |
| Normalized Basic EPS | 0.43 | 0.61 | 0.55 | 0.59 | 0.34 |
| EPS Diluted | 0.44 | 0.65 | 0.41 | 0.66 | 0.34 |
| Normalized Diluted EPS | 0.43 | 0.61 | 0.55 | 0.59 | 0.34 |
| Average Basic Shares Outstanding | 53.57M | 53.88M | 53.60M | 53.99M | 53.96M |
| Average Diluted Shares Outstanding | 53.57M | 53.88M | 53.60M | 53.99M | 53.96M |
| Dividend Per Share | -- | -- | 0.96 | -- | -- |
| Payout Ratio | -- | -- | 0.00% | 146.27% | -- |